Product Description
Mechanisms of Action: IL6 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Russia
Approved Indications: None
Known Adverse Events: None
Company: R-Pharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Moldova, Russia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: COVID-19
Phase 1: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RESET | P3 |
Active, not recruiting |
COVID-19 |
2022-10-31 |
39% |
| CL04041026 | P1 |
Completed |
Arthritis, Rheumatoid |
2022-06-08 |